Madrigal Pharmaceuticals (NASDAQ:MDGL) Insider Carole Huntsman Sells 419 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 419 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $431.94, for a total value of $180,982.86. Following the completion of the sale, the insider owned 12,692 shares in the company, valued at approximately $5,482,182.48. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Carole Huntsman also recently made the following trade(s):

• On Monday, January 26th, Carole Huntsman sold 910 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $493.78, for a total transaction of $449,339.80.

Madrigal Pharmaceuticals Price Performance

NASDAQ:MDGL traded down $6.51 during midday trading on Friday, hitting $432.83. 440,127 shares of the stock were exchanged, compared to its average volume of 375,225. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00. The business has a 50-day moving average price of $492.64 and a two-hundred day moving average price of $486.72.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). The firm had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The firm’s revenue for the quarter was up 210.8% compared to the same quarter last year. During the same quarter last year, the business posted ($2.71) earnings per share. Sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Wolfe Research set a $579.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Truist Financial increased their target price on shares of Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Barclays initiated coverage on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 27th. They set an “overweight” rating and a $964.00 target price for the company. Citizens Jmp upped their price target on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a “market outperform” rating in a report on Tuesday, January 20th. Finally, UBS Group set a $900.00 price objective on Madrigal Pharmaceuticals in a research report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $685.31.

Institutional Trading of Madrigal Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of MDGL. AlphaQuest LLC lifted its stake in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 66 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $428,000. Teacher Retirement System of Texas raised its holdings in shares of Madrigal Pharmaceuticals by 9.6% during the second quarter. Teacher Retirement System of Texas now owns 3,860 shares of the biopharmaceutical company’s stock valued at $1,168,000 after acquiring an additional 338 shares during the period. Spire Wealth Management raised its holdings in shares of Madrigal Pharmaceuticals by 150.0% during the second quarter. Spire Wealth Management now owns 250 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 150 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Madrigal Pharmaceuticals by 46.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 88,943 shares of the biopharmaceutical company’s stock valued at $26,918,000 after acquiring an additional 28,154 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.